US5196436A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dextromethorphan antitussive compositions
Assignee: Procter and Gamble Co
•
Filing: 1992-02-24
•
Granted: 1993-03-23
•
Expires: 2012-02-24
Abstract
Abstract The subject invention involves antitussive pharmaceutical compositions for the peroral administration of dextromethorphan, the composition being at a pH of from about 8 to about 11.
Inventors
- 👤 Ronald L. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 21:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0095; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K31/60
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
98 words
An antitussive composition, in dosage unit form, for peroral administration consisting essentially of a safe and effective amount of dextromethorphan and an orally-acceptable pharmaceutical carrier in the form of an aqueous-based liquid, or solid dissolvable in the mouth, selected from the group consisting of syrup, elixer, suspension, spray, lozenge, chewable lozenge, powder, and chewable tablet, the composition, or 10% artificial saliva solution thereof for solid dosage forms, being at a pH of about 8 to about 11, the carrier comprising a buffer system whereby the composition when mixed with saliva in the mouth is within such pH range.
Claim 2
Dependent Claim
98 words
An antitussive composition, in dosage unit form, for peroral administration consisting essentially of a safe and effective amount of dextromethorphan and an orally-acceptable pharmaceutical carrier in the form of an aqueous-based liquid, or solid dissolvable in the mouth, selected from the group consisting of syrup, elixer, suspension, spray, lozenge, chewable lozenge, powder, and chewable tablet, the composition, or 10% artificial saliva solution thereof for solid dosage forms, being at a pH of about 8 to about 11, the carrier comprising a buffer system whereby the composition when mixed with saliva in the mouth is within such pH range.
Claim 3
Dependent Claim
34 words
The composition of claim 1 wherein the composition has a basic buffer strength of at least about 0.01 mEq base per dose, and from about 1 mg to about 50 mg dextromethorphan per dose.
Claim 4
Dependent Claim
48 words
The composition of claim 2 wherein the composition is at a pH of from about 8.4 to about 10, has a basic buffer strength of from about 0.05 mEq to about 2.5 mEq per dose, and has from about 2.5 mg to about 30 mg dextromethorphan per dose.
Claim 5
Dependent Claim
12 words
The composition of claim 2 wherein the composition is an aqueous-based liquid.
Claim 6
Dependent Claim
23 words
The composition of claim 3 wherein the composition is an aqueous-based liquid which also comprises from about 0.5% to about 3% Avicel® RC591.
Claim 7
Independent Claim
29 words
A method of treating or preventing cough in humans by perorally administering to the human a safe and effective amount of a composition of claim any of claims 1-5.
Claim 8
Dependent Claim
17 words
The composition of any of claims 2, 3 or 5 wherein the composition is an aqueous-based solution.
Claim 9
Dependent Claim
16 words
The composition of any of claims 2, 3 or 5 wherein the composition is a lozenge.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-03-22 | 1996-09-21 | 1997-03-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-03-22 | 2000-09-21 | 2001-03-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-03-22 | 2004-09-21 | 2005-03-23 | $7700.00 | Window Closed / Lapsed |